Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock

Key Points

• CEO Helen Torley sold 20,000 Halozyme shares at an average price of $104.18, generating $2.08 million. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, leaving her with 767,780 shares.
• Halozyme shares rose to $107.62, near their 52-week high of $107.96. The company recently reported quarterly EPS of $2.28 and revenue of $481 million, exceeding analyst estimates and marking 47.7% year-over-year revenue growth.
• Analysts maintain a “Moderate Buy” consensus, with nine Buy, three Hold, and one Sell rating; recent price targets range from $93 to $115. Institutional investors and hedge funds own approximately 97.79% of the company.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00. Following the sale, the chief executive officer owned 767,780 shares in the company, valued at $79,987,320.40. This trade represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

• On Wednesday, July 8th, Helen Torley sold 1,923 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $79.77, for a total value of $153,397.71.
• On Wednesday, June 3rd, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.07, for a total transaction of $690,700.00.
• On Monday, June 1st, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $67.58, for a total transaction of $1,351,600.00.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock traded up $2.73 during mid-day trading on Wednesday, reaching $107.62. 2,539,028 shares of the stock traded hands, compared to its average volume of 2,401,815. The business has a 50-day moving average of $81.71 and a 200 day moving average of $73.26. Halozyme Therapeutics, Inc. has a fifty-two week low of $61.22 and a fifty-two week high of $107.96. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The stock has a market capitalization of $12.21 billion, a PE ratio of 32.13, a PEG ratio of 0.42 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to analysts' expectations of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm's quarterly revenue was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, analysts predict that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on HALO shares. Benchmark reissued a "buy" rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. TD Cowen boosted their price objective on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a "buy" rating in a report on Friday, August 7th. HC Wainwright upped their target price on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Wells Fargo & Company increased their price target on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an "equal weight" rating in a research report on Friday, August 7th. Finally, Morgan Stanley reduced their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating on the stock in a report on Tuesday, May 12th. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $91.20.

Institutional Trading of Halozyme Therapeutics

Large investors have recently bought and sold shares of the business. Measured Wealth Private Client Group LLC grew its stake in shares of Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 124 shares during the last quarter. Larson Financial Group LLC grew its holdings in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 343 shares during the period. MidFirst Bank purchased a new position in shares of Halozyme Therapeutics in the second quarter valued at $27,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Halozyme Therapeutics during the 2nd quarter valued at about $28,000. Finally, Quantbot Technologies LP purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter worth approximately $30,000. Institutional investors and hedge funds own 97.79% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source